NOTE 5 – INTANGIBLE ASSETS

Intangible assets at June 30, 2026 and December 31, 2025, consisted of the following:

During the six months ended June 30, 2026 and 2025, the Company recorded amortization expense from continuing operations of $45,587 and $0, respectively.

Licensed Technology

BP United

On May 12, 2026, as amended, the Company entered into a license agreement with BP United for an exclusive, sublicensable, perpetual, fully paid-up, worldwide license (unrestricted field of use) to BP United’s patents, trademarks, trade secrets, and know-how, together with a worldwide non-compete covenant from BP United. The licensed technology is applicable to multiple fields of use and applications, including, without limitation, drones, cyber technology, and other applications as the Company may determine. Consideration for the transaction was $1,000,000 cash and 20,000,000 restricted shares, vesting in four equal installments (September 30, 2026, March 31, 2027, June 30, 2027 and September 30, 2027).

The Company recognized Licensed Technology of $5,470,400, comprising $5,470,400 of stock payable within additional paid-in capital and prepaid technology expense of $1,000,000, related to twelve months of support by the licensor, recorded as the intellectual property acquisition liability. The Company used the grant-date price, net of discount for lack of marketability “DLOM” related to the issued shares being restricted (non-registered), of $0.2735/share for the 20,000,000 shares issued. As of June 30, 2026, the intellectual property acquisition liability remained outstanding at $1,000,000. The Company determined that the useful life of the license is 15 years.

Pancreatic Cancer Biomarker and Algorithm License Agreement

In March 2025, the Company entered into a license agreement with Liquid Biosciences (“Liquid”) to access and use a portfolio of novel mRNA biomarkers and related algorithms for the detection of pancreatic cancer through blood-based testing. Total consideration for the license is $1.2 million, payable in scheduled installments during 2025 and 2026. The Company recorded the acquired intellectual property as an indefinite-lived intangible asset.

The Company capitalized the license costs and recorded the license as an intangible asset, with a corresponding liability for amounts unpaid.

As of December 31, 2025, the impairment assessment did not indicate any impairment of an indefinite -lived intangible asset, and the Company concluded that the recoverability of an indefinite -lived intangible asset was not affected.

During the six months ended June 30, 2026, the Company paid $500,000 and an intellectual property acquisition liability was fully paid off.